SCHEMBL569878

SCHEMBL569878

[NH]C(=O)Nc1cccnc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.65
NPC1 O15118 3/20 0.65
PKM P14618 1/20 0.65
LMNA P02545 3/20 0.62
HIF1A Q16665 1/20 0.62
NAMPT P43490 4/20 0.61
TP53 P04637 1/20 0.59
GAA P10253 1/20 0.58
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57
ALDH1A1 P00352 3/20 0.57
KDM4E B2RXH2 2/20 0.57
CYP11B1 P15538 3/20 0.56
CYP11B2 P19099 3/20 0.56
CDK2 P24941 1/20 0.56
FLT4 P35916 1/20 0.56
HPGD P15428 1/20 0.56
MAPT P10636 1/20 0.56
ALOX15 P16050 1/20 0.56
HTT P42858 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30051982 0.83 MEN1 (0.77) RAB9ANPC1PKMLMNAHIF1A
SCHEMBL30504811 0.83 RAB9A (0.89) RAB9ANPC1PKMLMNAHIF1A
SCHEMBL9637653 0.83 MEN1 (0.77) RAB9ANPC1PKMLMNAHIF1A
Bromide SCHEMBL29417998 0.82 MEN1 (0.74) RAB9ANPC1PKMLMNAHIF1A
SCHEMBL967245 0.82 RAB9A (0.72) RAB9ANPC1PKMLMNAHIF1A
Hydrochloric Acid SCHEMBL29388210 0.82 MEN1 (0.74) RAB9ANPC1PKMLMNAHIF1A
SCHEMBL11213715 0.82 RAB9A (0.72) RAB9ANPC1PKMLMNAHIF1A
SCHEMBL6062650 0.82 RAB9A (0.67) RAB9ANPC1PKMLMNAHIF1A
SCHEMBL6877095 0.80 RAB9A (0.65) RAB9ANPC1PKMLMNAHIF1A
SCHEMBL49506 0.80 RAB9A (0.65) RAB9ANPC1PKMLMNAHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192646-A1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES UCB Biopharma SRL (BE) 2023-06-22 US claimed
EP-4081299-A1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES UCB Biopharma SRL (BE) 2022-11-02 EP claimed
WO-2021130255-A1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES UCB Biopharma SRL (BE) 2021-07-01 WO claimed
CN-112566910-A Thiophene derivatives for the treatment of IgE induced diseases UCB生物制药有限责任公司 2021-03-26 CN claimed
US-7494815-B2 Method and apparatus for analyzing compounds with amino group AJINOMOTO CO., INC. (JP) 2009-02-24 US claimed
US-20070269899-A1 METHOD AND APPARATUS FOR ANALYZING COMPOUNDS WITH AMINO GROUP AJINOMOTO CO. INC. (JP) 2007-11-22 US claimed
EP-1750126-A1 METHOD AND APPARATUS FOR ANALYZING AMINOFUNCTIONAL COMPOUND Ajinomoto Co., Inc. (JP) 2007-02-07 EP claimed
US-20230192646-A1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES UCB Biopharma SRL (BE) 2023-06-22 US disclosed
EP-4081299-A1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES UCB Biopharma SRL (BE) 2022-11-02 EP disclosed
WO-2021130255-A1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES UCB Biopharma SRL (BE) 2021-07-01 WO disclosed
US-9029536-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-12 US disclosed
US-20130172292-A1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-04 US disclosed
EP-2601192-A1 FUSED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2013-06-12 EP disclosed
WO-2009112275-A1 PESTICIDAL CONDENSED - RING ARYL COMPOUNDS BAYER CROPSCIENCE AG (DE) 2009-09-17 WO disclosed
US-7494815-B2 Method and apparatus for analyzing compounds with amino group AJINOMOTO CO., INC. (JP) 2009-02-24 US disclosed
US-20070269899-A1 METHOD AND APPARATUS FOR ANALYZING COMPOUNDS WITH AMINO GROUP AJINOMOTO CO. INC. (JP) 2007-11-22 US disclosed
EP-1750126-A1 METHOD AND APPARATUS FOR ANALYZING AMINOFUNCTIONAL COMPOUND Ajinomoto Co., Inc. (JP) 2007-02-07 EP disclosed
US-5922711-A ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, AUTOIMMUNE DISEASES, SHOCK OR ANALGESICS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-07-13 US disclosed
US-5750699-A HALOGENATING OF CORRESPONDING COMPOUND FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-05-12 US disclosed
US-5708173-A PREPARATION OF SUBSTITUTED QUINOLINE COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172292-A1 FUSED HETEROCYCLIC COMPOUNDS PDE10A, PDE3A, PDE2A RAB9A 64/4885NPC1 3068/4885PKM 3017/4885
US-20230192646-A1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES FCER2, FCGR2A, FCGR1A RAB9A 1222/4885NPC1 1018/4885PKM 4584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.